**Index**

absolute product protection see product protection

abstract ideas 3, 131, 146–51, 195–8
abuse see market power abuse
*Aerotel Ltd v Telco Holdings* 61, 64
Affymetrix 279
Agreement on Trade Related Aspects of Intellectual Property Rights see TRIPS
*AGREVO/Triazoles* case 58
agriculture 65, 135, 291
agrochemicals 94–6
algorithms 27, 147–8
Allison, John 13–14
*Amazon* case 58, 87, 170
AMD 120
American Civil Liberties Union (ACLU) 4, 264–7, 270, 272–3, 278, 280–86
*American Cyanamid Co (Dann’s) Patent* 88
*Amgen* case
*Amgen v. Chugai Pharm. Co.* 272, 282–3, 287
*Kirin-Amgen Inc v Hoescht Marion Rousell Ltd* 57–9, 89, 283
*Kirin-Amgen Inc v. Transkarvotic Therapies Inc.* 289, 296–7
amino acids 269–70, 272, 290
animal testing 235, 313, 315, 317–18
anticommons 21–3, 28–31, 137, 274
antitrust law 2, 126, 186, 195
Arora, Ashish 15
Arrow, Ken 18–19
Asahi Kasei Kogyo KK 289
Association for Molecular Pathology 264
*Astra Zeneca v Commission* 108, 112–13, 115, 121, 127
Australian High Court 66
Barker, Alyson 206
*BDPI Phosphatase/Max-Planck* case 291
Benkler, Yochai 336
Berne Convention 158
Bessen, James 135
BGH see German Federal Court
*Bilski v Kappos* 3, 193–218
*Biogen Inc v Medeva plc* 58, 88, 297
biological material 251, 253, 255
morality 236
scope of patents 222, 245–6, 249
excluded subject matter 298
invention requirement 80–83
morality 313
stem cell patentability 4
Blackberry 204
blastocyst 223, 241–3, 289, 319–20
blocking patents 21
BRCA 1 & 2 genes see breast cancer genes
breast cancer genes 4, 87, 263–5, 270–73, 277–87
Breyer, Justice 195–7
*British Airways v Commission* 123–4
British Technology Group 72
*Brüstle* case 240–43
Bundesgerichtshof (BGH) see German Federal Court
bundling 109, 114
Burk, Dan 216
business methods 145–51
*Bilski* case 193–7, 216–17
industry-specific patents 33, 35
invention categorization 87–8
patentability 2–3
protection exclusion 25–6, 59–61, 74, 163
US patents 143
Astra Zeneca case 121
Directive (87/54) 189
Directive (91/250) 125, 127
intellectual property 127
intellectual property rights 112–16
Lisbon Treaty 325
Microsoft case 120, 122, 124–5
Nice Charter 325
Regulation on Community Designs 190
European Commission Biotech Directive see Biotech Directive
European Council of Ministers Competitiveness Council 161
European Court of First Instance (CFI) 112
European Court of Human Rights 326, 334
European Court of Justice (ECJ) 72, 229
Biotech Directive 249
competition 122
monopoly 116
morality 325–6, 331, 333
stem cells 240–41
see also Court of Justice of the European Union (CJEU)
European General Court 112, 115, 122–3, 126
European Patent Convention 1–2, 299–302, 305, 312–19
computer program exclusion 86, 164
ethics 309
exclusions from patentable subject matter 56, 59–71, 74–6, 84–6, 157–9
Implementing Regulations 4, 69, 76, 313
industrial application requirement 225, 227–8, 291–3
insufficient disclosure 296
invention requirement 55–8, 62–76, 85, 87, 169–70
product patents 245
software patentability 146, 161–3
stem cell patents 234–9
European Patent Office 297–305
Biotech Directive conflict 234–5
Biotech Directive provisions 257
breast cancer (BRCA) susceptibility genes 263
disclosure 297
gene patenting 223
human embryo 243
industrial application requirement 227
invention requirement 59–63, 72, 74, 77, 80–83, 87, 89
jurisprudence 4, 71
legal uncertainty 159
morality 308, 316, 331, 333
Opposition Division 316–18
software definition 144–5
software patentability 58, 63, 171
software patents granted 156
stem cell patent refusal 322
stem cell patents 237
Technical Board of Appeal see Technical Board of Appeal
Euthanasia Compositions case 316
extraterritorial patent infringement 208–9
Exxon case 62, 82–3, 89
Fair, Reasonable and Non-Discriminatory Terms (FRAND) 105, 108–9
Federal Circuit see United States Court of Appeal of the Federal Circuit (CAFC)
Federal Trade Commission (FTC) 262–4, 283–4
first-to-invent priority system 194, 217
Food and Drug Administration (FDA) 24, 96–7, 283, 285
fragmentation 89, 136–7, 140, 310, 314
free software 175, 178–9
see also open source
Freeman Walter Abele test 148
Fujitsu Ltd case 59, 63
G_003/8 case, President Reference/Computer Program Exclusion, decision by the Enlarged Board of Appeal of the EPO 56, 131, 145–6, 166–7
GenBank 273
gene fragment 29, 269, 272–3, 279–80
gene patenting 4, 260–87
gene sequencing 4, 29, 249, 265, 267
generic drugs 127, 283
manufacturers 24, 29, 33
market dominance 105, 108, 121
patent expiry 93–6
Generics v Lundbeck 56, 85
genetically modified 232, 244, 247, 249, 260, 314–18
gene
artificial 289, 295, 307
human 267, 275, 285
Genomic Research and Diagnostic Accessibility Act 284
Georgia-Pacific Corp. v United States Plywood Corp 214
German Federal Court 167–8, 240–42
German law 149
German Patent Act 142
Germany 75, 228–9, 240
Ghosh, Professor Shubha 202
Ginsburg, Justice 195–6
H2 blockers 113
Haase, Heiko 133
Hague Court 247–9
Halliburton Energy Services Inc v Smith International Inc 59–60, 64
Heller, Michael 21
Hematopoietic cytokine receptor/Zygogenetics 292
hemoglobin 269–70
heterogeneity 10, 13–15
HGS see Eli Lilly v Human Genome Sciences Inc
Hoffman, Lord 59, 61–3, 88, 197
horticulture 65
House of Lords see United Kingdom
human embryo 241–5, 289–327
patent exclusion 4, 222, 235–43
human embryonic stem cells (hESC) 236–43, 289, 301–8, 319–25, 330–35
morality 315
patentability 4
pluripotent 321
human genome see genome, human
IBM 125
IBM/Computer Program Product I 164, 171
IBM/Computer Program Product II 164
IMS Health GmbH & Co v NDC Health GmbH & Co 112, 124
In re Bilski 71, 149, 194, 198, 199
incremental improvement 27–8, 40
industrial application 290–95, 307–8
gene patenting 223–9
invention requirement 71–6, 234, 298
software patentability 161
industry-specific legislation 33–9
absolute product protection 254
business methods 195–6
computer programs 86
experimental exemption 103
gene patenting 262–4, 271–80
genetic testing 284–5
insufficiency 296
Microsoft case 108
Monsanto case 247–9
morality 317
software patentability 176
injunction 197, 203–6, 276, 280
biotechnology 262–4, 310
cumulative see cumulative innovation
damages 212
intellectual property 107–9
Microsoft case 124–6
sequential 135
software patentability 152
strategic patenting 140
Intel case 108, 120
intellectual property 12, 15–20, 28, 31–2, 330
law 153, 210, 336
protection 329
see also TRIPS
intellectual property rights (IPR) 104–21
morality 309, 311, 328, 335
patent value 182
product protection 127–8
software patentability 156
interface 150–51
International Patent Classification (IPC) 133

Emanuela Arezzo and Gustavo Ghidini - 9780857938039
Downloaded from Elgar Online at 03/12/2019 01:19:22AM via free access
Interoperability 27, 117, 124–5, 137–40
Invention
   Definition 82
   Requirement 2, 55–90
IVF treatment 303
Jacob, Lord Justice 61
Jensen, Kyle 267–70
Joint Electron Device Engineering Council (JEDEC) 113, 116
Kennedy, Justice 195–6
Kirin-Amgen Inc v Hoescht Marion Roussel Ltd see Amgen
Kitch, Edmund 16–17
Kitchin, Justice 293
Kokott, Advocate General 123
KSR International Co v Teleflex Inc 197, 215–16
La Jolla Cancer Research Foundation 278
Laddie, Justice 59, 63
Landes, William 20
Leahy, Senator Patrick 209, 214, 217
Lear Corporation 211
Leland case 318
Lemley, Mark 13–14, 19, 216
License 15, 30, 48, 108, 120, 187
   Agreements 51
      Compulsory 105, 107, 119, 124, 127, 185–6
      Fees 275
      Manufacturing 118
      Non-discriminatory 47
      Non-voluntary 186
      Open-source 51
      Royalties 276
      Sub-licenses 47, 49, 51
      System 50
      Technology transfer 111–12
      Voluntary 51, 212
see also Cross-licensing
Ligand Pharmaceuticals 278
Lisbon Treaty 325
Long, Clarissa 216
Losec 113, 115
Lourie, Judge 200–201
Lucent Technologies Inc v Gateway Inc 213–14
Luxembourg Convention on the Community Patent (CPC) 91–2
Machlup, Fritz 135, 191
Madey v Duke University 97
Magill case 116, 124
Market power abuse 105, 107, 109–13, 116–27
see also Dominance
Market power acquisition 117–18, 121
Market share 114–16
Marshall, Texas 210
Maskin, Eric 135
Mengozzi, Advocate General 82, 229–30
Merges, Robert 19–20, 216
Merrell Dow Pharmaceuticals v HB Norton & Co Ltd 59, 61, 63
Metabolites 199–201
Micro-organisms 88, 260
Microarray 269, 279–80
Microprocessor 11, 31
see also Semiconductor industry
Microsoft 117
   Money 213–14
   Outlook 213–14
   Windows 114, 122, 213
   Windows Mobile 213–14
Microsoft Corp v AT&T Corp 208–9
Microsoft Corp v Commission 108, 112–16, 120, 122, 124
Mobil 72
Monopoly 17–19, 89, 115–19, 293
Anticommons 22
Bilski v. Kappos case 196
Competitive innovation 25
Invention requirement 62
Stem cell patents 297–8
see also Dominance; Market power abuse
Monsanto Technology LLC v Cefetra BV et al. 73, 83, 229–30, 234, 247–56, 258
Moore, Kimberly 14
Morality 4, 235–6, 288, 298–337
   Biotech Directive 222
   European Union 242
Exclusion 76
Patent exclusion 258
Morse, Samuel 150–51
research and development 11, 24–5
strategic patenting 108

PHOSITA 37–8
Plant Genetic Systems 316
plant patents 221, 244–6
plasmid 246
policy levers 10, 32, 37–9
polynucleotide probes 265–6
polypeptide 272, 292
pooling patents see patent pool
technique
Posner, Richard 20
Prescott, Peter, QC 60–61, 74
pricing policy 115
primary product markets 108, 111–12,
115–17
product protection 250
absolute 225–34, 250–51, 254–5, 258
purpose-bound 83, 224–9, 233–4
programmer 11, 88, 170, 173–8, 183
Prometheus Laboratories Inc v Mayo
Collaborative Services 199–201
prospect theory 16–21, 24–5, 29
protein 272–3, 291
coding 248
DNA sequence 29
erthropoietin 282
production 227, 246
synthetic 270, 289
proton pump inhibitor (PPI) 112–13,
115, 121
PTO see United States Patent and
Trademark Office
Pumfrey, Justice 60–61, 64, 74
purpose-bound product protection see
product protection

Quanta Computer Inc v LG Electronics
Inc 197

Rambus case 113, 115–16, 120
Read Corp v Portec Inc 206
recombinant cell 272–3
recombinant erythropoietin 282
Relaxin case 316
research and development 11, 24–6,
117, 329, 331
research exemption 91–104
Romer, Lord Justice 296
Index

Rooklidge, Bill 206, 216
Roundup-Ready (RR) soya 247
royalties 108–9, 118, 212, 270, 276–80, 332
eBay case 204
FRAND 113
patent pool 47
reach-through licenses 30
RTE 116
SACGHS Report 279, 281, 284
Scalia, Justice 195, 197
Schlumberger Holdings Ltd v Electromagnetic Geoservices AS 78
Schumpeter, Joseph 17–19
Seagate case 207–8
secondary product markets 111–12, 117, 120
Secretary’s Advisory Committee on Genetics, Health and Society (SACGHS) 280–81
Semiconductor Chip Protection Act (SCPA) 36
semiconductor industry 11–14, 32–3, 35–6, 113, 120, 189
patent thickets 23, 31
Shapiro, Carl 23
Sherman Act 117
SIEC 111
SLC 111
small and medium-sized enterprises (SMEs) 173–6
socio-economic analysis 161, 172
software
definition 132–4, 142–5
patentability 134, 159–61, 171, 173, 188
software patents granted 156
Sotomayer, Justice 195–6
soya 247–52
standardization 12, 47, 113, 138
State Street Bank & Trust Co. v. Signature Financial Group 196
Statute of Monopolies 65–6
stem cells see human embryonic stem cells (hESC)
Stevens, Justice 196
Strasbourg Convention 311
strategic patenting 108, 139–40
supplementary protection certificate (SPC) 112, 127
Switzerland 135
Symbian v Comptroller General of Patents 61–2, 81
synthetic biology 288–308
Technical Board of Appeal see European Patent Office
TFEU see Treaty on the Functioning of the European Union (TFEU)
Thomas, Justice 205
Treaty on the Functioning of the European Union (TFEU) 105, 110–13, 117–26, 333
TRIPS 35, 80, 83–4, 142, 329–31
biotech patents 311
EBA declaration 239
Monsanto case 250
morality 334
software 152, 158
stem cells 288, 306
see also intellectual property; intellectual property rights (IPR)
trivial patents 140, 170, 178, 181, 184
TS Tech USA Corp case 211–12
United Kingdom
Court of Appeal 61, 78, 81, 227, 296
House of Lords 55, 62, 89, 289
law 145–6
United States Code Section (101) 199, 266
United States Congress 207–18, 264, 283–4, 334
Patent Reform Acts 202–3
patent term length 33
patentability 146, 152
United States Constitution 141, 266, 335–7
United States Court of Appeal of the Federal Circuit (CAFC) 25, 203–11, 214–16, 265, 336
business methods 149, 194
patent infringement 94
research exemption 97
United States legal system 334
<table>
<thead>
<tr>
<th>United States Patent and Trademark Office</th>
<th>334–5</th>
</tr>
</thead>
<tbody>
<tr>
<td>bacterium patentability</td>
<td>260</td>
</tr>
<tr>
<td>biotechnology patents</td>
<td>290</td>
</tr>
<tr>
<td>business methods</td>
<td>147</td>
</tr>
<tr>
<td>cancer gene patents</td>
<td>264–5</td>
</tr>
<tr>
<td>Congress</td>
<td>216–17</td>
</tr>
<tr>
<td>gene patent issuing</td>
<td>275</td>
</tr>
<tr>
<td>gene patenting</td>
<td>267</td>
</tr>
<tr>
<td>Guidelines</td>
<td>3–4, 198, 262–3</td>
</tr>
<tr>
<td>invention requirement</td>
<td>170</td>
</tr>
<tr>
<td>Manual of Patent Examination Procedure</td>
<td>148</td>
</tr>
<tr>
<td>patentability</td>
<td>194</td>
</tr>
<tr>
<td>software patentability</td>
<td>158</td>
</tr>
<tr>
<td>United States Supreme Court</td>
<td>193–218</td>
</tr>
<tr>
<td><em>Bilski</em> case</td>
<td>3</td>
</tr>
<tr>
<td>business methods</td>
<td>149–51</td>
</tr>
<tr>
<td><em>Diamond v Chakrabarty</em></td>
<td>267</td>
</tr>
<tr>
<td>infringement damages</td>
<td>276</td>
</tr>
<tr>
<td>micro-organism patentability</td>
<td>260–61</td>
</tr>
<tr>
<td>research exemption</td>
<td>96</td>
</tr>
<tr>
<td>software patentability</td>
<td>131</td>
</tr>
<tr>
<td>University of Utah Research Foundation</td>
<td>265</td>
</tr>
<tr>
<td>university research</td>
<td>97, 99–100, 266, 275, 285</td>
</tr>
<tr>
<td>USPTO see United States Patent and Trademark Office</td>
<td></td>
</tr>
<tr>
<td>venue</td>
<td>202–3, 209–12</td>
</tr>
<tr>
<td>Vienna Convention on the Law of Treaties</td>
<td>64, 80</td>
</tr>
<tr>
<td><em>Volvo v Veng</em></td>
<td>111, 115, 120</td>
</tr>
<tr>
<td>Von Hellfeld, Axel</td>
<td>142</td>
</tr>
<tr>
<td>Walker, Lord</td>
<td>85</td>
</tr>
<tr>
<td>Weyand, Joachim</td>
<td>133</td>
</tr>
<tr>
<td><em>Whittemore v Cutter</em></td>
<td>91</td>
</tr>
<tr>
<td>willful infringement</td>
<td>203, 206–7, 277</td>
</tr>
<tr>
<td><em>Wisconsin Alumni Research Foundation</em> (WARF) decision</td>
<td>4, 290, 301–2, 307–8, 322–4, 332</td>
</tr>
<tr>
<td>World Intellectual Property Organization (WIPO)</td>
<td>158, 188–9</td>
</tr>
</tbody>
</table>